Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Frontier Medicines has raised $20.0M in total funding. The most recent round was Series C. The last funding was announced in June 2024.
Frontier Medicines's investors include RA Capital Management, DCVC Bio, Deerfield Management, Deerfield, ArrowMark Partners.
Frontier Medicines is headquartered in San Francisco, United States.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Frontier Medicines is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Frontier Medicines — Funding & Investors." VCBacked, June 25, 2024, https://www.vcbacked.co/company/frontier-medicines. Accessed August 5, 2026.
VCBacked. (2024). Frontier Medicines — Funding & Investors. Retrieved August 5, 2026, from https://www.vcbacked.co/company/frontier-medicines
{{cite web |title=Frontier Medicines — Funding & Investors |url=https://www.vcbacked.co/company/frontier-medicines |website=VCBacked |access-date=August 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated